Gregory P. Botta

机构：UC San Diego Health System, University of California San Diego, Center for Personalized Cancer Treatment, Laboratory for Personalized Molecular Medicine, Moores Cancer Center · ORCID：0000-0001-9606-4508

发表论文 85 篇 · 总被引 1218 次 · h-index 16

代表论文

• Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma (2024 · The Oncologist · 被引 40)
• Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells (2024 · Journal for ImmunoTherapy of Cancer · 被引 33)
• CLDN18.2 chimeric antigen receptor T cell therapy for patients with advanced gastric and pancreatic adenocarcinoma: Results of ELIMYN18.2 phase 1b clinical trial. (2024 · Journal of Clinical Oncology · 被引 14)
• Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations (2024 · Journal of Clinical Oncology · 被引 11)
• Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer (2025 · Annals of Surgery · 被引 6)
• Abstract B033: Petosemtamab (MCLA-158) monotherapy or with chemotherapy in metastatic colorectal cancer: Preliminary antitumor activity and safety data from a phase 2 trial (2025 · Molecular Cancer Therapeutics · 被引 5)